StreetAlpha
13F holdings · Q3 2026

Remedium Capital Partners

West Palm Beach, FL · files as Remedium Capital Partners, LLC
Know the moment Remedium Capital Partners filesYou follow Remedium Capital Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 2104501

Remedium Capital Partners reported 6 stocks worth $274M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are SYRE (37.8%), ORKA (29.1%) and DMRA (15.9%). Compared with Q2 2026, the fund opened new positions in DMRA and KRSA, added to JBIO and trimmed SYRE and ORKA.

Latest filing: what Remedium Capital Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
2 new1 added2 trimmed2 sold outBought about $63.4M · sold about $209M
New 2
Added 1
Trimmed 2
Sold out 2
  • Apogee Therapeutic$77.9M
  • Galecto Inc$53.2M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$274M−39.4% vs last quarter
Stocks held62 new · 2 sold out
Top 5 weight98.1%very concentrated
Turnover100%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
SYRE
Spyre Therapeutics Inc
$103M37.8%1.2M−304K (−21%)4 of 4
2
ORKA
Oruka Therapeutics Inc
$79.5M29.1%954K−612K (−39%)4 of 4
3
DMRA
Damora Therapeutics Inc
$43.5M15.9%2MNew position1 of 4
4
JBIO
Jade Biosciences Inc
$25.4M9.3%1.8M+230K (+15%)4 of 4
5
KRSA
Korsana Biosciences Inc
$16.6M6.1%519KNew position1 of 4
6
CBIO
Crescent Biopharma Inc.
$5.3M1.9%361KNo change2 of 4

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
APOGEE THERAPEUTICS INC
$77.9M587K
GALECTO INC
$53.2M2M

Reported value

last 4 quarters
$170MQ4 '25
$281MQ1 '26
$452MQ2 '26
$274MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Remedium Capital Partners 13F FAQ

What does Remedium Capital Partners own?

Remedium Capital Partners reported 6 stocks worth $274M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are SYRE (37.8%), ORKA (29.1%) and DMRA (15.9%). The table above lists every position in the filing (the top 10 without an account).

What did Remedium Capital Partners buy and sell in Q3 2026?

Compared with Q2 2026: 2 new positions, 1 added to, 2 trimmed and 2 sold out. New positions include DMRA and KRSA.

When will Remedium Capital Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Remedium Capital Partners's portfolio worth?

The Q3 2026 filing reports $274M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.